| Overview |
| bs-3164R-PE-Cy5 |
| FAK (Tyr407) Polyclonal Antibody, PE-Cy5 Conjugated |
| WB, FCM |
| Human, Mouse |
| Rat, Dog, Cow, Sheep, Horse, Rabbit |
| Specifications |
| PE-Cy5 |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human FAK around the phosphorylation site of Tyr407 |
| Tyr407 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5747 |
| Q05397 |
| Cytoplasm, Nucleus, Cell membrane |
| FAK phospho Y407; p-FAK phospho Y407; FADK 1; FADK; FAK 1; FAK related non kinase polypeptide; FAK1; Focal adhesion kinase 1; FRNK; pp125FAK; Protein tyrosine kinase 2; Protein Tyrosine Kinase Cytoplasmic; PTK 2; FAK1_HUMAN; Focal adhesion kinase-related nonkinase; Protein phosphatase 1 regulatory subunit 71; PPP1R71; Protein-tyrosine kinase 2; p125FAK. |
| Non-receptor protein-tyrosine kinase implicated in signaling pathways involved in cell motility, proliferation and apoptosis. Activated by tyrosine-phosphorylation in response to either integrin clustering induced by cell adhesion or antibody cross-linking, or via G-protein coupled receptor (GPCR) occupancy by ligands such as bombesin or lysophosphatidic acid, or via LDL receptor occupancy. Plays a potential role in oncogenic transformations resulting in increased kinase activity. [SUBCELLULAR LOCATION] Cell junction, focal adhesion. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Note=Constituent of focal adhesions. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
Powered by Bioz